Oxford Debate: Pharma using CROs vs not outsourcing clinical trials

Do pharma & biotech companies need CROs or is it better not to outsource clinical trials at all? In recent years, partnerships and outsourcing have grown rapidly in popularity, promising cheaper, faster, more successful trials. However, there are still plenty of challenges to be overcome and for some, these challenges are so numerous that they outweigh the benefits of such collaborations.

At Partnerships in Clinical Trials Europe 2016 four leading drug development professionals debated this vital question with an audience vote before and after. Watch the arguments below (or watch it here) and find out if they managed to sway an audience firmly behind the benefits of outsourcing.